Insulet tops quarterly estimates on demand for wearable insulin pumps
Medical device maker Insulet on Thursday posted third-quarter results that surpassed Wall Street's expectations on strong demand for its wearable insulin pumps, which eliminate the need for daily injections.
Ahead of Insulet (PODD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Insulet (PODD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.
Here's Why Insulet (PODD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet Corporation (PODD) Presents At Baird Global Healthcare Conference 2025 Transcript
Insulet Corporation (NASDAQ:PODD ) Baird Global Healthcare Conference 2025 September 9, 2025 12:15 PM EDT Company Participants Eric Benjamin - Executive VP & COO Ana Chadwick - Executive VP & CFO Conference Call Participants Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Presentation Jeffrey Johnson Senior Research Analyst Jeff Johnson.
Insulet Corporation (PODD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Insulet Corporation (NASDAQ:PODD ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 3:00 PM EDT Company Participants Ashley McEvoy - CEO, President & Director Ana Chadwick - Executive VP & CFO Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst All right. Welcome back.
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet Gains 77.2% in a Year: What's Driving the Rally?
PODD's 77.2% stock surge is fueled by Omnipod 5 expansion, global launches, strong Q2 profits and robust financial stability.
Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold
PODD delivered strong Q2 results, exceeding revenue guidance, improving gross margin, and launching the Omnipod 5 iPhone app, strengthening its ecosystem position. Omnipod 5's pharmacy channel penetration and positive clinical data support sustained >20% annual revenue growth and margin expansion over the next 3-5 years. The market underestimates the long-term impact of pharmacy distribution, which reduces onboarding friction, broadens payer access, and improves retention economics.
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
